Work

Survival-adjusted health-related quality of life (HRQL) among patients with metastatic breast cancer receiving paclitaxel plus bevacizumab versus paclitaxel alone: results from Eastern Cooperative Oncology Group Study 2100 (E2100)

Year: 2011

Type: article

Source: Breast Cancer Research and Treatment

DOI: 10.1007/s10549-011-1725-6

Authors: David Cella, Molin Wang, Lynne Wagner, Kathy Miller

Institutions: Northwestern University, Harvard University, Dana-Farber Cancer Institute, Dana-Farber/Harvard Cancer Center, Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Indiana University Health, Indiana University Melvin and Bren Simon Comprehensive Cancer Center, Indiana University

Language: English

Topic: Cancer survivorship and care

Subfield: Oncology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: green

Funders: National Institutes of Health, National Cancer Institute

Awards: G1011812605, Eastern Cooperative Oncology Group, ECOG Statistical Office Data Management Grant, G1422427855, G1628476732, G2679961467, G3762168461, G3996959562, G4412485521, G5765316850, Eastern Cooperative Oncology Group Operations Office, G964706321

OpenAlex ID: W1978510597

FWCI: 2.48

Cites: 12

Cited by: 42

Related to: 10